FORM PTO-1449 (Rev. 2-92) U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.:	065435-9014
SERIAL NO.:	10/069,202
APPLICANT:	Thurston *et al.*
FILING DATE:	February 22, 2002
GROUP:	1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
O.K.	1	3,523,941	11 Aug 1970	Leimgruber *et al*	260	239.3	
	2	3,524,849	18 Aug 1970	Batcho *et al*	260	239.3	
	3	4,239,683	16 Dec 1980	Takanabe *et al*	260	239.3	
	4	4,309,437	05 Jan 1982	Ueda *et al*	424	274	
	5	5,143,854	01 Sep 1992	Pirrung *et al*	436	518	
	6	5,545,568	13 Aug 1996	Ellman	436	518	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
O.K.	7	1 299 198	06 Dec 1972	Great Britain				
	8	2 586 683	06 Mar 1987	France				X
	9	WO 88/04659	30 June 1988	PCT/US				
	10	WO 91/16324	31 Oct 1991	PCT/US				
	11	WO 92/19620	12 Nov 1992	PCT/FR				X
	12	WO 96/23947	08 Aug 1996	PCT/US				
	13	WO 97/01560	16 Jan 1997	PCT/US				
	14	WO 97/07097	27 Feb 1997	PCT/NZ				
	15	WO 98/11101	19 Mar 1998	PCT/NZ				
	16	WO 99/29642	17 Jun 1999	PCT/US				
	17	WO 00/12506	09 Mar 2000	PCT/GB				
	18	57-131791	14 Aug 1982	Japan				X
	19	58180487 A	21 Oct 1983	Japan				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

O.K.	20	Althuis, T.H. *et al.*, "Synthesis and identification of the major metabolites of Prazosin formed in dog and rat," 20:1, 146-149 (1977).
	21	Aristoff, P.A. *et al.*, "Synthesis of CBI-PDE-I-Dimer, the benzannelated analogue of CC-1065," *J.Org.Chem.*," 57, 6234-6239 (1992).
	22	Aristoff, P.A. *et al.*, "Synthesis of biochemical evaluation of the CBI-PDE-I-dimer, a benzannelated analog of (+)-CC-1065 that also produces delayed toxicity in mice," *J.Med.Chem.*, 36, 1956-1963 (1993).
	23	Baraldi, P.G. *et al.*, " Design, synthesis and biological activity of a pyrrolo [2,I-c][1,4] benzodiazepine (PBD)-distamycin hybrid," *Bioorg. Med. Chem. Ltrs.*, 8, 3019-3024 (1998).
	24	Bi, Y. *et al*, "Building blocks for peptide and carbamate libraries," *Bioorg. Med. Chem. Ltrs*, 6:19, 2299-2300 (1996).
	25	Bi, Y., *et al*, "Building blocks for peptide and carbamate libraries," *Chemical Abstracts,* 300965y, 125:23, p.1013 (1996).

EXAMINER Bruce Kisliuk DATE CONSIDERED 10/12/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-92) U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.:	065435-9014
SERIAL NO.:	10/069,202
APPLICANT:	Thurston *et al.*
FILING DATE:	February 22, 2002
GROUP:	1624

B.C.	26	Boger, D.L., "Design, synthesis, and evaluation of DNA minor groove binding agents: the duocarmycins," *Pure & Appl. Chem.*, 66:4, 837-844 (1994).
	27	Boger, D.L. *et al.*, "Total synthesis and evaluation of ±-N-(*tert*-butyloxycarbonyl)-CBI (±)-CBI-CDPI$_1$, and (±)-CBI-CDPI$_2$ CC-1065 functional agents incorporating the equivalent 1,2,9,9a-tetrahydrocycloprop[1,2-c]benz[1,2-e]indol-4-one(CBI) left-hand subunit," *J. Am. Chem Soc.*, 111:16, 6461-6463 (1989).
	28	Boger, D.L. *et al.*, "Synthesis of N-(*tert*-butyloxycarbonyl)-CBI,CBI,CBI-CDPI$_1$,and CBI-CDPI$_2$: Enhanced functional analogues of CC-1065 incorporating the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) left-hand subunit,". *Org. Chem.*, 55:23, 5823-5832 (1990).
	29	Boger, D.L. *et al.*, "An efficient synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benz[e] indol-4-one (CBI): An enhanced and simplified analog of the CC-1065 and duocarmycin alkylation subunits," *J. Org. Chem.*, 60:5, 1271-1275 (1995).
	30	Boger, D.L. *et al.*, "CBI-TMI: Synthesis and evaluation of a key analog of the duocarmycins. Validation of a direct relationship between chemical solvolytic stability and cytotoxic potency and confirmation of the structural features responsible for the distinguishing behavior of enantiomeric paris of agents," *J. Am. Chem. Soc.*, 116:18, 7996-8006 (1994).
	31	Boger, D.L. *et al.*, "CC-1065 and the duocarmycins: synthetic studies," *Chem. Rev.*, 97:3, 787-828 (1997).
	32	Bose, D.S *et al.*, "New approaches to pyrrolo[2,1-c][1,4]benzodiazepines: synthesis, DNA-binding and cytotoxicity of DC-81," *Tetrahedron*, 48:4, 751-758 (1992).
	33	Bose, D.S. *et al.*, "Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system," J. am. Chem. Soc., 114:12, 4939-4941 (1992).
	34	Brown, S.C. *et al.*, "NMR solution structure of a peptide nucleic acid complexed with RNA," *Science*, 265, 777-780 (1994).
	35	Burgess, K. *et al.*, "Solid phase syntheses of oligoureas," *J. Am. Chem. Soc.*, 119:7, 1556-1564 (1997).
	36	Burgess, K. *et al.*, "Solid-phase syntheses of unnatural biopolymers containing repeating urea units," *Agnew. Chem. Int. Ed. Engl.*, 34:8, 907-909 (1995).
	37	Cava, M.P. & Drost, K.J., "A photochemically based synthesis of the benzannelated analogue of the CC-1065 A unit," *J. Org. Chem.*, 56:6, 2240-2244 (1991).
	38	Cho, C.Y. *et al.*, "An unnatural biopolymer," *Science*, 261, 1303-1305 (1993).
	39	Courtney, S.M. *et al.*, "A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines," *Tetrahedron Ltrs.*, 34:33, 5327-5328 (1993).
	40	Edman, P. *et al.*, "A protein sequenator," *European J. Biochem.*, 1:1, 80-91 (1967).
	41	Egholm, M. et al, "Peptide nucleic acids (PNA). Oligonucleotide analogues with an achiral peptide backbone," *J. Am. Chem. Soc.*, 114, 1895-1897 (1992).
	42	Egholm, M. *et al.*, "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," *Nature*, 365, 566-568 (1993).
	43	Farmer, J.D., Jr. *et al.*, "DNA binding properties of a new class of linked anthramycin analogs," *Chemical Abstract*, 239940r, 114:25, p.25 (1991).

EXAMINER Bruce Kisliuk DATE CONSIDERED 10/13/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-92) U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.:	065435-9014
SERIAL NO.:	10/069,202
APPLICANT:	Thurston *et al.*
FILING DATE:	February 22, 2002
GROUP:	1624

B.K.	44	Figliozzi, G.M. *et al.*, "Synthesis of N-substituted glycine peptoid libraries," *Methods in Enzymology*, 267:25 437-47 (1996).
	45	Foloppe, M.P. *et al.*, "DNA-binding properties of pyrrolo[2,1-c][1,4]-benzodiazepine N10-C11 amidines," *Eur. J. Med. Chem.*, 31, 407-410 (1996).
	46	Fujisawa Pharm., "Benzodiazepine derivatives," *Chemical Abstracts*, 139983k, 99:17, 603 (1983).
	47	Fujisawa Pharm., "Benzodiazepine derivatives," *Chemical Abstracts*, 72145x, 98:9, 638 (1983).
	48	Fukuyama, T. *et al.*, "Total synthesis of (+)-porothramycin B," *Tetrahedron Ltrs.*, 34:16, 2577-80 (1993).
	49	Furka, A. *et al.*, "General method for rapid synthesis of multicomponent peptide mixtures," *In. J. Peptide Protein Res.*, 37 487-493 (1991).
	50	Gregson, S.J. *et al.*, "Synthesis of a novel C2/C2'-*exo* unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity," *Chem. Commun.*, 797-798 (1999).
	51	Guiotto, A. *et al.*, "Synthesis of novel C7-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) via pro-N10-troc protection and suzuki coupling," *Bioorg. Med. Chem. Ltrs.*, 8:21, 3017-3018 (1998).
	52	Hara, M. *et al.*, "A new glycosidic pyrrolo[1,4]benzodiazepine antibiotic produced by *streptomyces* sp." *J. Antibiotics*, 41:5, 702-704 (1988).
	53	Hochlowski, J.E. *et al.*, "Abbeymycin, a new anthramycin-type antibiotic produced by a *streptomycete*," *J. of Antibiotics*, 40:2, 145-148 (1987).
	54	Hurley, L.H. *et al.*, "Covalent binding of antitumor antibiotics in the minor groove of DNA. Mechanism of action of CC-1065 and the pyrrolo[1,4]benzodiazepines," *Acc. Chem. Res.*, 19, 230-237 (1986).
	55	Itoh, J. *et al.*, "Sibanomicin, a new pyrrolo[1,4]benzodiazepine antitumor antibiotic produced by a *micromonospora* sp.," *J. Antibiotics*, 41:9,1280-1284 (1988).
	56	Jenkins, T.C. *et al.*, "Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: Evidence for sequence-specific interstrand cross-linking," *J. Med. Chem.*, 37:26, 4529-4537 (1994).
	57	Kohn, K.W., "Anthramycin," *Antibiotics, III*, 3-11 (1975).
	58	Konishi, M. *et al.*, "Chicamycin, a new antitumor antibiotic II. Structure determination of chicamycins A and B," *J. Antibiotics*, 37:3, 200-206 (1984).
	59	Kunimoto, S. *et al.*, "Mazethramycin, a new member of anthramycin group antibiotics," *J. Antibiotics*, 33:6, 665-667 (1980).
	60	Langley, D.R. *et al.*, "A versatile and efficient synthesis of carbinolamine-containing pyrrolo[1,4]benzodiazepines via the cyclization of N-(2-aminobenzoyl)pyrrolidine-2carboxaldehyde diethyl thioacetals: Total synthesis of prothracarcin," *J. Organ. Chem.*, 52:1, 91-97 (1987).
	61	Leber, J.D. *et al.*, "A revised structure for sibiromycin," *J. Am. Chem. Soc.*, 110:9, 2992-2993 (1988).

EXAMINER Brenda Kiffle DATE CONSIDERED 10/13/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-92)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.: 065435-9014
SERIAL NO.: 10/069,202
APPLICANT: Thurston *et al.*
FILING DATE: February 22, 2002
GROUP: 1624

B.K.	62	Leimgruber, M. *et al.*, "The structure of anthramycin," *J. Am. Chem. Soc.*, 87:24, 5793-5795 (1965).
	63	Leimbruger, M. *et al.*, "Isolation and characterization of anthramycin, a new antitumor antibiotic," *J. Am. Chem. Soc.*, 87:24, 5791-5793 (1965).
	64	Lescrinier, T. *et al.*, "DNA-binding ligands from peptide libraries containing unnatural amino acids," *Chem. Eur. J.*, 4:3, 425-433 (1998).
	65	Lown, J.W. *et al.*, "Antitumor antibiotics," *Biochem. Pharmacol.*, 28:13, 2017-2026 (1979).
	66	Monks, A. *et al.*, "Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines," *J. of Nat'l Cancer Inst.*, 83:11, 757-765 (1991).
	67	Moran, E.J. *et al.*, "Novel biopolymers for drug discovery," *Peptide Science*, 37, 213-219 (1995).
	68	Nagasaka, T. *et al.*, "Stereoselective synthesis of tilivalline," *Tetrahedron Letters*, 30:14, 1871-1872 (1989).
	69	Nagasaka, T. *et al.*, "Stereoselective synthesis of tilivalline," *J. Org. Chem.*, 63:20, 6797-6801 (1998).
	70	Nielsen, P.E. *et al.*, "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide," *Science,* 254, 1497-1500 (1991).
	71	O'Neil, Ian *et al.*, "The synthesis of functionalized pyrrolo[2,1-e][1,4]-benzodiazepines," *Chemical Abstracts*, 126:13, 618 (1997) and entire article.
	72	O'Neil, Ian A. *et al.*, "DPPE: A convenient replacement for triphenylphosphine in the Staudinger and Mitsunobu reactions," *Tetrahedron Letters*, 39:42, 7787-7790 (1998).
	73	Paikoff, S.J. *et al.*, "The solid phase synthesis of N-alkylcarbamate oligomers," *Tetrahedron Letters*, 37:32, 5653-5656 (1996).
	74	Rawal, V.H. *et al.*, "Photocyclization strategy for the synthesis of antitumor agent CC-1065: Synthesis of dideoxy PDE-I and PDE-II. Synthesis of Thiophene and Furan analogues of dideoxy PDE-I and PDE-II, *J. Org. Chem.*, 52:1, 19-28 (1987).
	75	Reynolds, V.L. *et al.*, "The chemistry, mechanism of action and biological properties of CC-1065, a potent antitumor antibiotic," *J. Antibiotics*, 39:3, 319-334 (1986).
	76	Saha, A.K. *et al.*, "Diisopropylsilyl-linked oligonucleotide analogs: Solid-phase synthesis and physicochemical properties," *J. Org. Chem.*, 58:27, 7827-7831 (1993).
	77	Schreiber, S.L., Kapoor, T.M. *et al.*, "Exploring the specificity pockets of two homologous SH3 domains using structure-based, split-pool synthesis and affinity-based selection," *J. Am. Chem. Soc.*, 120:1, 23-29 (1998).
	78	Shimizu, K. *et al.*, "Prothracarcin, a novel antitumor antibiotic," *J. Antibiotics*, 35:8, 972-978 (1982).
	79	Simon, R.J. *et al.*, "Peptoids: A modular approach to drug discovery," *Proc. Natl. Acad. Sci. USA*, 89, 9367-9371 (1992).
	80	Soth, M.J. *et al.*, "Unnatural oligomers and unnatural oligomer libraries," *Curr. Opin. Chem. Biol.*, 1:1, 120-129 (1997).

EXAMINER B.K. DATE CONSIDERED 10/13/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Rev. 2-92) U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.:	065435-9014
SERIAL NO.:	10/069,202
APPLICANT:	Thurston *et al.*
FILING DATE:	February 22, 2002
GROUP:	1624

S.K.	81	Takeuchi, T. *et al.*, "Neothramycins A and B, new antitumor antibiotics," *J. Antibiotics*, 29:1, 93-96 (1976).
	82	Thurston, D.E. *et al.*, "Synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines," *Chem. Rev.* 94:2, 433-465 (1994).
	83	Thurston, D.E. *et al.*, "The molecular recognition of DNA," *Chem. Britain*, 26, 767-772 (1990).
	84	Thurston, D.E. *et al.*, "Synthesis of a novel GC-specific covalent-binding DNA affinity-cleavage agent based on pyrrolobenzodiazepines (PBDs)," *Chem. Commun.*, 563-565 (1996).
	85	Thurston, D.E., "Advances in the study of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour antibiotics," *Molecular Aspects of Anticancer Drug-DNA Interaction*, Neidle, S., Waring, M.J., Eds.; Macmillan Press Ltd., v.1, 54-88 (1993).
	86	Thurston, D.E. *et al.*, "Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c],[1,4]benzodiazepines," *J. Med. Chem.* 42:11, 1951-1964 (1999).
	87	Tsunakawa, M. *et al.*, "Porothramycin, a new antibiotic of the anthramycin group: production, isolation, structure and biological activity," *J. Antibiotics*, 41:10, 1366-1373 (1988).
	88	Umezawa, H. *et al.*, "Mazethramycins," *Chemical Abstracts*, 90:1, 428 (1979).
	89	Wilson, S.C. *et al.*, "Design and Synthesis of a novel epoxide-containing pyrrolo[2,1-c][1,4]benzodiazepine (PBD) via a new cyclization procedure," *Tetrahedron Ltrs.*, 36:35, 6333-6336 (1995).
	90	Zuckermann, R.N. *et al.*, "Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted)blycine peptoid library," *J. Med. Chem.*, 37:17, 2678-2685 (1994).

Q:\CLIENT\065435\9014\B0135416.1

EXAMINER Brenda Kiff DATE CONSIDERED 10/13/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.